OR WAIT null SECS
September 07, 2026
Video
Rahul Aggarwal, MD, MBA, shares the results of his retrospective cohort study investigating the residual risk of heart failure after patients with prior MI.
August 29, 2026
Article
POET-II found tailored antibiotics cut treatment duration by a third in left-sided infective endocarditis without compromising safety, per ESC 2026 data.
Philippe Gabriel Steg, MD, discusses the full results of the terminated trial, reflecting on their impact on the ongoing LIBREXIA-AF and LIBREXIA-Stroke trials.
August 18, 2026
Philippe Généreux, MD, discusses a secondary analysis of EARLY TAVR examining patients excluded from the trial for positive treadmill stress tests.
August 07, 2026
The phase 3 trial of evolocumab showed cardioprotective effects in patients without prior MI or stroke, regardless of qualifying atherosclerosis or background therapy.
August 01, 2026
July saw some of the biggest FDA approvals so far in 2026 – catch up on what you might have missed!
July 31, 2026
All cardiovascular disease risks decreased proportionately across all quintiles of diet consistency, according to recent data.
July 30, 2026
Benjamin van Boxtel, MD, discusses the importance of familial screening for aortic dissection and the danger of missing potential risk factors.
CaRi-Heart measures coronary inflammation from routine CT angiography and generates a personalized 10-year cardiovascular mortality risk score.
July 16, 2026
A recent analysis of data from the Global Burden of Disease Study has indicated a relationship between risk of death from ACHD and socioeconomic factors.
